Wedbush Reiterates Outperform Rating for Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a research note issued on Friday,Benzinga reports. They currently have a $4.00 target price on the stock. Wedbush’s price objective would indicate a potential upside of 175.86% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research report on Thursday, January 30th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Price Performance

NASDAQ GOSS opened at $1.45 on Friday. Gossamer Bio has a 12 month low of $0.50 and a 12 month high of $1.55. The stock has a market cap of $328.58 million, a price-to-earnings ratio of -4.53 and a beta of 1.86. The company’s 50 day moving average is $1.13 and its two-hundred day moving average is $0.97. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). The company had revenue of $9.38 million for the quarter, compared to the consensus estimate of $7.02 million. As a group, research analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Jefferies Financial Group Inc. purchased a new position in shares of Gossamer Bio in the fourth quarter valued at $90,000. Mackenzie Financial Corp grew its holdings in shares of Gossamer Bio by 499.0% in the fourth quarter. Mackenzie Financial Corp now owns 299,815 shares of the company’s stock valued at $271,000 after purchasing an additional 249,765 shares in the last quarter. Velan Capital Investment Management LP purchased a new position in shares of Gossamer Bio in the fourth quarter valued at $68,000. Two Sigma Investments LP grew its holdings in shares of Gossamer Bio by 41.3% in the fourth quarter. Two Sigma Investments LP now owns 891,279 shares of the company’s stock valued at $806,000 after purchasing an additional 260,318 shares in the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of Gossamer Bio by 44.7% in the fourth quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company’s stock valued at $1,047,000 after purchasing an additional 357,500 shares in the last quarter. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.